Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Lenz

Showing results (251-260 of 294) with videos related to

Pageof 30
Sort By:
Blood Advances|April 9, 2025
The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potentialMiriam Verdú-Bou, Maria Joao Baptista, Marcelo Lima Ribeiro, et al.
JAMA Oncology|February 9, 2023
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical TrialMartin Bornhäuser, Christoph Schliemann, Johannes Schetelig, et al.
Leukemia|August 10, 2023
Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease formsSabrina Kalmbach, Michael Grau, Myroslav Zapukhlyak, et al.
Blood Cancer Journal|June 2, 2026
Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysisPhilipp Berning, Markus Maulhardt, Hristo Boyadzhiev, et al.
Journal of Hematology & Oncology|December 2, 2022
Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemiaNicole Bäumer, Annika Scheller, Lisa Wittmann, et al.
Hemasphere|August 20, 2025
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysisMarkus Maulhardt, Simon Call, Hristo Boyadzhiev, et al.
Cancers|June 11, 2020
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation StudyChristoph Schliemann, Mirjam Gerwing, Hauke Heinzow, et al.
Leukemia|March 29, 2018
The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphomaNikolai Schleussner, Olaf Merkel, Mariantonia Costanza, et al.
Blood|January 15, 2025
Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemiaJulian Ronnacker, Michael Grau, Maximilian Klasmeier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracyWilliam W L Choi, Dennis D Weisenburger, Timothy C Greiner, et al.
Pageof 30

Showing results (251-260 of 294) with videos related to

Sort By:
Pageof 30
Blood Advances|April 9, 2025
The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potentialMiriam Verdú-Bou, Maria Joao Baptista, Marcelo Lima Ribeiro, et al.
JAMA Oncology|February 9, 2023
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical TrialMartin Bornhäuser, Christoph Schliemann, Johannes Schetelig, et al.
Leukemia|August 10, 2023
Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease formsSabrina Kalmbach, Michael Grau, Myroslav Zapukhlyak, et al.
Blood Cancer Journal|June 2, 2026
Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysisPhilipp Berning, Markus Maulhardt, Hristo Boyadzhiev, et al.
Journal of Hematology & Oncology|December 2, 2022
Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemiaNicole Bäumer, Annika Scheller, Lisa Wittmann, et al.
Hemasphere|August 20, 2025
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysisMarkus Maulhardt, Simon Call, Hristo Boyadzhiev, et al.
Cancers|June 11, 2020
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation StudyChristoph Schliemann, Mirjam Gerwing, Hauke Heinzow, et al.
Leukemia|March 29, 2018
The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphomaNikolai Schleussner, Olaf Merkel, Mariantonia Costanza, et al.
Blood|January 15, 2025
Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemiaJulian Ronnacker, Michael Grau, Maximilian Klasmeier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2009
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracyWilliam W L Choi, Dennis D Weisenburger, Timothy C Greiner, et al.
Pageof 30